Volume 7, Number 6—December 2001
Research
Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination
Table 3
Age Years | No. vaccine doses | No. of OAE*a | OAE* reported/ 100,000 doses | RRR (95% CI) | #SyAE*b | SyAE* reported/ 100,000 doses | RRR (95% CI) |
---|---|---|---|---|---|---|---|
15-24 | 189,991 | 12 | 6.32 | 1.8 (0.9-3.5) | 2 | 1.05 | 3.7 (0.5-26) |
25-44 | 702,783 | 25 | 3.56 | Reference | 2 | 0.29 | Reference |
45-64 | 442,605 | 15 | 3.39 | 1.0 (0.5-1.8) | 5 | 1.13 | 4.0 (0.8-20) |
65-74 | 86,222 | 3 | 3.48 | 1.0 (0.3-3.2) | 3 | 3.48 | 12.3 (2.0-73) |
>75 | 22,085 | 2 | 9.06 | 2.5 (0.6-10.7) | 2 | 9.06 | 32 (4.5-226) |
Total | 1,443,686 | 57 | 3.95 | 14 | 0.97 |
aOAE*= other adverse events (i.e., uncomplicated neurologic or systemic event; hypersensitivity; local reaction) OR systemic adverse events not requiring hospitalization or resulting in death.
bSyAE* = serious systemic adverse events, including only neurologic or multisystemic adverse events requiring hospitalization or resulting in death; this is distinguished from the term SyAE, which indicates all systemic adverse events (See Table 2).
CI = confidence intervals.
1Jeff Altman, University of Washington, Seattle, Washington; Vernon Ansdell, Kaiser Permanente, Honolulu, Hawaii; Elizabeth Barnett, Boston University, Boston, Massachusetts; Michele Barry Yale University, New Haven, Connecticut; Bradley Connor, Cornell University, New York, New York; David Freedman, University of Alabama at Birmingham, Birmingham, Alabama; Alejandra Gurtman, Mount Sinai Medical Center, New York, New York; Elaine Jong, University of Washington, Seattle, Washington; Phyllis Kozarsky, Emory University, Atlanta, Georgia; Russell McMullen, University of Washington, Seattle, Washington; Jan Patterson, University of Texas, San Antonio, Texas; Bradley Sack, Johns Hopkins University, Baltimore, Maryland; Mary E. Wilson, Harvard University, Cambridge, Massachusetts; Martin Wolfe, Traveler's Medical Service of Washington, Washington, D.C.